Log in

Relevant bibliographies by topics / Cleopatra III

Academic literature on the topic 'Cleopatra III'

Author: Grafiati

Published: 10 December 2022

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Journal articles
Books
Book chapters
Conference papers

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cleopatra III.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cleopatra III"

1

Pearce, Sarah. "THE CLEOPATRAS AND THE JEWS." Transactions of the Royal Historical Society 27 (November 1, 2017): 29–64. http://dx.doi.org/10.1017/s0080440117000032.

Full text

Abstract:

ABSTRACTThis paper explores a variety of evidence for relations between Cleopatra VII, the last Ptolemaic ruler of Egypt, and her Jewish subjects. In the first part of the paper, the focus is on the profoundly negative portrait of the queen in the works of Josephus, with particular attention to Cleopatra's alleged antipathy to Alexandrian Jews in Josephus's Against Apion. Analysis of Josephus's evidence confirms, I argue, that his case against the queen does not stand up. The second part of the paper offers a detailed consideration of other evidence, epigraphic and literary, which, I suggest, confirms a picture of the queen as continuing the policy of her predecessors with regard to the Jews of the Ptolemaic kingdom, by participating in the long-established practice of extending royal support and protection to Jewish proseuchai (places of prayer). While the evidence does not permit definitive conclusions, it suggests that Cleopatra looked to particular Jewish groups – as to others – within Egypt for support and in this, followed a path taken by Cleopatra II and Cleopatra III. Finally, a few details in Plutarch's Life of Antony may also suggest the queen's political and personal alliances with individual Jews, in Egypt and Judea.

APA, Harvard, Vancouver, ISO, and other styles

2

Musgrave, Jonathan. "Dust and Damn'd Oblivion: A Study of Cremation in Ancient Greece." Annual of the British School at Athens 85 (November 1990): 271–99. http://dx.doi.org/10.1017/s0068245400015689.

Full text

Abstract:

In this paper – the revised text of a public lecture given in Athens on 23 February 1989 – the author reviews both the historical and anatomical evidence for identifying the occupants of the royal tombs at Vergina as: Tomb I: not known; Tomb II: Philip II and either Cleopatra or Meda; Tomb III: Alexander IV. The case for Philip III Arrhidaios and Eurydice in Tomb II is shown to be anthropologically weak. The paper also includes a catalogue of the human remains from Tomb II antechamber (Cleopatra or Meda) and Tomb III (Alexander IV). The arrival of cremation in Greece, and both Homeric and later Macedonian attitudes to the rite are also discussed. The general conclusion is that cremations are a valuable source of biological and archaeological information.

APA, Harvard, Vancouver, ISO, and other styles

3

Urruticoechea, Ander, Seock-Ah Im, Montserrat Munoz, Jose Baselga, Denise A. Yardley, Sarah Heeson, Sarah Jones, et al. "Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 1023. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.1023.

Full text

Abstract:

1023 Background: T-DM1 was approved for pts with HER2+ MBC previously treated with trastuzumab (H) and a taxane based on the phase III EMILIA study. P in combination with H + docetaxel (T) later became the first-line standard of care for HER2+ MBC, but there are limited data on T-DM1 efficacy in pts who previously received P. We present exploratory efficacy results from pts treated with T-DM1 any time after P from 2 phase III studies: CLEOPATRA and PHEREXA. Methods: CLEOPATRA (NCT00567190) and PHEREXA (NCT01026142) are randomized, 2-arm trials evaluating P-based regimens for HER2+ MBC. CLEOPATRA studies H + T + P vs HT + placebo in pts with no prior anti-HER2 treatment (tx) or chemotherapy for MBC, while PHEREXA studies H + capecitabine (C) +/− P in pts who progressed during/after previous H tx for MBC. We assessed overall survival (OS) in an exploratory analysis of pts who either received or did not receive T-DM1 at any time after discontinuing study-assigned tx in CLEOPATRA or PHEREXA. Results: Of 408 pts who received HTP in CLEOPATRA and 228 pts who received HCP in PHEREXA, 32 and 43 pts received subsequent T-DM1, respectively (Table). Median duration of T-DM1 tx was 7.1 mo (range 0−44) and 4.2 mo (range 0−22), respectively, and median time from discontinuation of P to start of T-DM1 was 3.5 mo (range 1−47) and 10.6 mo (range 1−28). Conclusions: Although data are limited in these exploratory analyses, our results provide additional evidence of T-DM1 clinical activity in pts with HER2+ MBC who progressed on prior P + H, a finding with real-world implications. Clinical trial information: NCT00567190, NCT01026142. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

4

Lenzo, Giuseppina. "A Xoite Stela of Ptolemy VIII Euergetes II with Cleopatra II and Cleopatra III (British Museum EA 612)*." Journal of Egyptian Archaeology 101, no. 1 (January 2015): 217–37. http://dx.doi.org/10.1177/030751331510100111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Henning, Peter. "Metastasiertes HER2-positives -Mamma-Karzinom: Erstlinientherapie mit Pertuzumab." Onkologische Welt 03, no. 04 (2012): 172. http://dx.doi.org/10.1055/s-0038-1630202.

Full text

Abstract:

Die Phase-III-Studie CLEOPATRA (Clinical Evaluation Of Pertuzumab And TRAstzumab) zeigt eine statistisch signifikante und klinisch relevante Verbesserung des progressionsfreien überlebens durch Pertuzumab bei HER2 positivem metastasiertem Mamma- Karzinom in der Erstlinientherapie (1), so das Fazit von Prof. Andreas Schneeweiss, Leiter der Sektion Gynäkologische Onkologie am Nationalen Centrum für Tumorerkrankungen, Heidelberg.

APA, Harvard, Vancouver, ISO, and other styles

6

Xu, Binghe, Wei Li, Qingyuan Zhang, Shao Zhimin, Wang Xiao Jia, Huiping Li, Tao Sun, et al. "A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 1026. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1026.

Full text

Abstract:

1026 Background: In CLEOPATRA (NCT00567190), adding P to H + D significantly improved progression-free and overall survival (PFS/OS) v Pla + H + D in patients (pts) with previously untreated HER2-positive LR/MBC. PUFFIN (NCT02896855) is a China bridging study; the objective being to assess consistency of efficacy with CLEOPATRA. Methods: Pts with previously untreated HER2-positive LR/MBC were randomized 1:1 to P + H + D or Pla + H + D, stratified by visceral v non-visceral disease and hormone receptor status. The primary endpoint was investigator-assessed PFS. Secondary endpoints included objective response rate (ORR in pts with measurable baseline disease), OS, and safety. The target sample size (240) was determined based on the consistency threshold for PFS, defined as hazard ratio (HR) < 0.81, which maintains ≥ 50% of the risk reduction determined in CLEOPATRA (HR 0.62). Results: Two hundred forty-three pts were randomized. Baseline/disease characteristics and prior therapies were generally balanced between arms. For PFS, the HR was 0.69 (95% CI 0.49, 0.99) in the ITT population. No cases of heart failure or symptomatic left ventricular ejection fraction decline were reported. Efficacy/safety are shown in the table. Conclusions: PUFFIN met its primary endpoint. Overall, efficacy data were consistent with CLEOPATRA (ITT population and Asian subgroup). Safety was also consistent and in line with the known P safety profile, with no new or unexpected signals reported. PUFFIN adds to the totality of data with P in previously untreated HER2-positive LR/MBC, and supports the favorable benefit–risk profile of P in Chinese pts. Clinical trial information: NCT02896855. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

7

Gómez Lara, Manuel José. "«'O, Never was there queen/ So mightly Betray'd' (I,iii,24-5): Locura de amor en "Antony and Cleopatra"»." Philologia Hispalensis 1, no. 2 (1987): 17–28. http://dx.doi.org/10.12795/ph.1987.v02.i01.02.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ciruelos Gil, Eva Maria, Adam Brufsky, Young-Hyuck Im, Sung-Bae Kim, Emma Clark, Adam Knott, Graham Ross, and David Miles. "Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 600. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.600.

Full text

Abstract:

600 Background: CLEOPATRA is a global phase III trial of P + T + D vs placebo + T + D in HER2-positive 1L MBC. Results showed a significant improvement in PFS (Baselga NEJM 2012) and OS (Swain SABCS 2012) favoring P + T + D. CLEOPATRA started recruitment in 2008 soon after the approval of T in the adjuvant setting in 2006 and mandated a disease-free interval (DFI) of ≥12 mos from the end of adjuvant therapy to MBC diagnosis. Due to this, a low proportion of pts with prior T exposure was included. Here we present the efficacy and safety of 1L P + T + D in the subset of pts in CLEOPATRA with prior T exposure. Methods: Pts received P + T + D or placebo + T + D, had a DFI ≥12 mos, baseline left ventricular ejection fraction (LVEF) ≥50% and no LVEF decline to <50% during/after prior T therapy. Exploratory analyses of PFS and OS in pts with (neo)adjuvant therapy with or without T were conducted. Results: Of the study population, 47% had received (neo)adjuvant therapy and 11% had received (neo)adjuvant T; 82% of the prior T group came from Europe or North America. A univariate Cox regression analysis did not identify prior T therapy as a statistically significant risk factor for developing left ventricular systolic dysfunction (LVSD). However, due to the low number of LVSD events overall, this analysis has limited sensitivity. Conclusions: Data from CLEOPATRA show that pts with HER2-positive 1L MBC who have received prior T (DFI ≥12 mos) derive the same magnitude of benefit from the combination of P + T + D when compared with the whole study population or those who are T-naïve. This is in agreement with prior evidence of the activity of P + T in pts pretreated with T (Baselga JCO 2010). Efficacy and safety of P-T-based therapy is being explored in the PERUSE and PHEREXA trials, in a pt population with wider exposure to prior T and a shorter DFI, which may better represent current clinical practice. Clinical trial information: NCT00567190. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

9

Baselga, José, and Sandra M. Swain. "CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer." Clinical Breast Cancer 10, no. 6 (December 2010): 489–91. http://dx.doi.org/10.3816/cbc.2010.n.065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ali, Ali. "THE COLUMN OF CLEOPATRA III AND PTOLEMY IX FROM KOM OMBO IN THE GEM (45481)." Shedet 7, no. 7 (December 31, 2020): 1–25. http://dx.doi.org/10.21608/shedet.2021.32773.1020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Cleopatra III"

1

Die Glossen der Hs. British Library, Cotton Cleopatra A. III: Phonologie, Morphologie, Wortgeographie. Frankfurt am Main: P. Lang, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Charnes, Linda. Notorious identity: Materializing the subject in Shakespeare. Cambridge, Mass: Harvard University Press, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Marie, Hacht Anne, ed. Shakespeare for students: Critical interpretations of Shakespeare's plays and poetry. 2nd ed. Detroit: Thomson Gale, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Robert, Sandler, ed. Northrop Frye on Shakespeare. New Haven: Yale University Press, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Frye, Northrop. Northrop Frye on Shakespeare. New Haven: Yale University Press, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Thompson, Dorothy J. Cleopatra III. Oxford University Press, 2015. http://dx.doi.org/10.1093/acrefore/9780199381135.013.1671.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

George, Margaret. Memorias de Cleopatra III. Santillana USA Publishing Company, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

George, Margaret. Memorias de Cleopatra III. Ediciones B, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

George, Margaret. Memorias de Cleopatra: Ocaso de una Diosa Vol III. Ediciones B, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Findlay, Alison. ‘Make My Image but an Alehouse Sign’. Edited by Jonathan Post. Oxford University Press, 2013. http://dx.doi.org/10.1093/oxfordhb/9780199607747.013.0010.

Full text

Abstract:

Queen Margaret’s words ‘Make my image but an alehouse sign’ in 2 Henry VI (III. ii. 81) offer an appropriate metaphor for the female voice in Shakespeare’s texts because they advertise the ways female characters strive to speak out within a discursive environment that silences them as images. The chapter explores how women in Shakespeare’s plays negotiate a space to speak within a poetic discourse that repeatedly objectifies them as signs, focusing on Catherine’s role in Henry V and the blason, and the Jailer’s Daughter’s self-inscription into a ballad tradition in Two Noble Kinsmen. A second section uses the analytic tools provided by corpus-linguistics to explore the poetic voices of tragic female characters: Lady Macbeth, Cleopatra, and the women of Richard III. The essay concludes by tracing the growth of an independent, poetic female voice in the role of Queen Margaret who offers an ironic commentary on Shakespeare's growing sense of his own identity as national bard.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Cleopatra III"

1

"CLEOPATRA II, CLEOPATRA III, AND PTOLEMY VIII." In Cleopatras, 141–51. Routledge, 2002. http://dx.doi.org/10.4324/9780203036082-15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

"CLEOPATRA III AND HER CHILDREN." In Cleopatras, 152–68. Routledge, 2002. http://dx.doi.org/10.4324/9780203036082-16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

"III. Literaturverzeichnisse." In Ibrahim (Bassa), Cleopatra (Erst- und Zweitfassung), 1247–68. Walter de Gruyter, 2008. http://dx.doi.org/10.1515/9783110210972.1247.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Bowden, Hugh. "2. Prince: Alexander in the Macedonian court." In Alexander the Great: A Very Short Introduction, 23–31. Oxford University Press, 2014. http://dx.doi.org/10.1093/actrade/9780198706151.003.0003.

Full text

Abstract:

‘Prince: Alexander in the Macedonian Court’ looks at Alexander's childhood and at a number of women who played an important part in his upbringing, such as his mother, Olympias; Eurydice, wife of Amyntas III; and Cleopatra, his sister. Of the Alexander historians, only Plutarch talks about Alexander the Great's childhood, telling many stories about Alexander's mother. Alexander maintained a close relationship with his mother throughout his life and he corresponded with her regularly. Alexander's life in the Macedonian court was interrupted when he went into exile and shortly after his father was assassinated at his sister's wedding leaving Alexander heir.

APA, Harvard, Vancouver, ISO, and other styles

5

"Sovereign Rapture: The Enigma of Pushkin’s Cleopatra." In Two Hundred Years of Pushkin, Volume II, 53–70. BRILL, 2003. http://dx.doi.org/10.1163/9789004484047_007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Thonemann, Peter. "2. From Alexander to Augustus." In The Hellenistic Age: A Very Short Introduction, 15–39. Oxford University Press, 2018. http://dx.doi.org/10.1093/actrade/9780198746041.003.0002.

Full text

Abstract:

‘From Alexander to Augustus’ describes the twists and turns of Hellenistic history, from Alexander’s accession (336 bc) to Cleopatra’s death and the end of the Ptolemaic kingdom (30 bc). It begins by outlining Alexander’s reign and the first generation after his death (323–281 bc), when his empire fractured into three successor kingdoms, each ruled by a Macedonian king: the Antigonids in Macedon, the Ptolemies in Egypt, and the Seleucids in western and central Asia. The rising power of the imperial city-states of Carthage and Rome is described, including Rome’s victories over Philip V and Antiochus III during the 2nd century bc. It ends with the final period of the Hellenistic age (133–30 bc).

APA, Harvard, Vancouver, ISO, and other styles

7

Kuligowska-Korzeniewska, Anna. "Modrzejewska i Rapacki." In Helena Modrzejewska : materiały do badań nad życiem i twórczością aktora II połowy XIX i początków XX wieku, 85–108. Ksiegarnia Akademicka Publishing, 2022. http://dx.doi.org/10.12797/9788381387293.04.

Full text

Abstract:

Helena Modjeska and Wincenty Rapacki – eminent representatives of the 19th-century ‘age of stars’ – met on provincial stages at the beginning of their acting careers. In 1863, they performed in thirty plays together, including Mazepa by J. Słowacki, Barbara Radziwiłłówna by A. Feliński, and Hernani by V. Hugo, in Stanisławów and Czerniowce. Some of these creations, such as Adrianna Lecouvreur and Michonnet in the play by E. Scribe and E. Legouvé, were enthusiastically received and the actors brought them to Krakow (since 1865), which testifies to their talents and the meticulous preparation of the parts. In Krakow, they appeared together in about forty performances (vaudevilles, operettas, comedies, tragedies, and melodramas) mainly of French origin as well as historical dramas on Polish themes. Owing to the theater director S. Koźmian and Rapacki, most prominent in this repertoire were parts in Shakespeare’s tragedies and comedies. These creations (among others, Julia and Friar Laurence in Romeo and Juliet, Desdemona and Iago in Othello, Cleopatra and Enobarbus in Antony and Cleopatra, and Viola and Malvolio in Twelfth Night) made Modjeska famous as a preeminent Shakespearean actress and she was partnered in the Warsaw Government Theaters by the most esteemed artists (J. Królikowski, B. Leszczyński, B. Ładnowski and W. Rapacki)

APA, Harvard, Vancouver, ISO, and other styles

8

"THE STORY OF CLEOPATRA'S NEEDLE." In ENGINEERING WONDERS OF THE WORLD VOLUME II., 22–28. Thomas Telford Publishing, 2011. http://dx.doi.org/10.1680/ewotwv2.50914.0002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cleopatra III"

1

Schmullius, Christiane C., and Juergen Nithack. "Temporal multiparameter airborne DLR E-SAR images for crop monitoring: summary of the CLEOPATRA campaign 1992." In Satellite Remote Sensing III, edited by Giovanna Cecchi, Guido D'Urso, Edwin T. Engman, and Preben Gudmandsen. SPIE, 1997. http://dx.doi.org/10.1117/12.264275.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Miles, D., A. Fung, B. Yoo, A. Knott, S. Heeson, C. Portera, and S. Swain. "Abstract P4-14-27: Effect of docetaxel duration on clinical outcomes: Results from the phase III trial CLEOPATRA." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p4-14-27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Baselga, J., J. Cortés, S.-A. Im, E. Clark, A. Kiermaier, G. Ross, and SM Swain. "Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-s5-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Swain, SM, Y.-H. Im, S.-A. Im, D. Miles, A. Knott, E. Clark, G. Ross, and J. Baselga. "Abstract P4-12-10: Safety of pertuzumab (P) with trastuzumab (T) and docetaxel (D) in patients (pts) from Asia with HER2-positive metastatic breast cancer (MBC): Results from the phase III trial CLEOPATRA." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-p4-12-10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Baselga, J., S.-B. Kim, S.-A. Im, R. Hegg, Y.-H. Im, L. Roman, JL Pedrini, et al. "S5-5: A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial To Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Patients with Previously Untreated HER2−Positive Metastatic Breast Cancer (CLEOPATRA)." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-s5-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Swain, SM, S.-B. Kim, J. Cortes, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, et al. "Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p5-18-26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Descloitres, Jacques, Jean-Claude Buriez, Frederic Parol, and Claudine Vanbauce. "Cloud reflectance as measured from POLDER during CLEOPATRA, ASTEX, and EUCREX." In Satellite Remote Sensing II, edited by Richard P. Santer. SPIE, 1995. http://dx.doi.org/10.1117/12.228536.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!